Roivant Sciences (ROIV) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings or view top-rated stocks.

8 brokerages have issued 12 month target prices for Roivant Sciences' shares. Their ROIV share price forecasts range from $10.00 to $23.00. On average, they predict the company's share price to reach $15.38 in the next year. This suggests a possible upside of 22.5% from the stock's current price.
View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts.

Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV stock has increased by 57.1% and is now trading at $12.55.
View the best growth stocks for 2023 here.

Roivant Sciences saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 18,340,000 shares, a decrease of 13.4% from the August 31st total of 21,190,000 shares. Based on an average daily volume of 4,980,000 shares, the short-interest ratio is presently 3.7 days. Currently, 3.6% of the shares of the stock are sold short.
View Roivant Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ROIV earnings forecast.

Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 1,233.11% and a negative trailing twelve-month return on equity of 73.68%. The company's revenue was up 402.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.48) earnings per share.

ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3X Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ROIV stock can currently be purchased for approximately $12.55.

Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $9.69 billion and generates $61.28 million in revenue each year. The company earns $-1,009,030,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

The company employs 904 workers across the globe.

Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347.